Randomized Phase III Trial Comparing Everolimus Plus Placebo Versus Everolimus Plus Bevacizumab for Advanced Renal Cell Carcinoma Progressing After Treatment With Tyrosine Kinase Inhibitors.
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Jan 2018
At a glance
- Drugs Bevacizumab (Primary) ; Everolimus (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 22 Nov 2017 Planned primary completion date changed from 30 Jun 2019 to 31 Jul 2018.
- 10 Jun 2017 Biomarkers information updated
- 25 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.